ArticleResearch and practice in thrombosis and haemostasis2026
Nationally representative estimates of health care burden of venous thromboembolism in hospitalized cancer patients.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The public health impact of cancer-associated venous thromboembolism: looking to the future.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous thromboembolism (VTE) is a frequent and often preventable cancer-related comorbidity. Objectives: This study evaluated national health care burden of patients hospitalized with cancer and VTE diagnoses. Methods: The 2021 Nationwide Inpatient Sample was used to generate nationally representative estimates of cancer-associated thrombotic events identified via International Classification of Diseases-10 coding. Adjusted odds ratios (aOR) for co-diagnosis rate and all-cause mortality, median hospital charges, and length of stay (LOS) for cancer admissions with and without VTE were calculated. Results: Of 28,443,009 adult US hospitalizations in 2021, 2,907,118 (10.2%) listed cancer as a diagnosis. Of these, 234,090 (8.1%) had co-diagnosis of VTE: pulmonary embolism (PE), 96,335 (41%); deep vein thrombosis (DVT), 172,315 (74%); and PE+DVT, 34,560 (15%). Median age for admissions with cancer and VTE was 67 years (IQR, 58-76 years), with 87.6% admissions classified as major/severe underlying illness. VTE and cancer occurred at significantly higher rates than noncancer admissions (adjusted odds ratio [aOR], 1.81; 95% CI, 1.79-1.83; Conclusions: This report on contemporary national data shows co-diagnosis of VTE and cancer is associated with significantly higher all-cause mortality, LOS, and total hospital expenditures than cancer admissions without VTE. These findings underscore importance of accurate VTE risk assessment for inpatients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.